MiRNA-543 inhibited PRMT9-enhanced cellular oxidative phosphorylation, and when miRNA-543 was absent, this promoted PRMT9 to increase HIF-1α instability and inhibit glycolysis in osteosarcoma cells [154], suggesting that miR-543/PRMT9/HIF-1α targeting the glycolytic pathway may be a potential therapeutic strategy to eradicate osteosarcoma cells. The gene discussed is PRMT9; the disease is osteosarcoma.